STAAR Surgical Company (STAA) and ENDRA Life Sciences Inc. (NASDAQ:NDRA) Contrasting side by side

STAAR Surgical Company (NASDAQ:STAA) and ENDRA Life Sciences Inc. (NASDAQ:NDRA), are influenced by compare since they are both players in the Medical Instruments & Supplies. These factors are particularly influence the institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation of the two firms.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
STAAR Surgical Company 117.62M 13.79 3.73M 0.22 155.16
ENDRA Life Sciences Inc. N/A 1151.24 9.73M -2.48 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for STAAR Surgical Company and ENDRA Life Sciences Inc.

Profitability

Table 2 provides STAAR Surgical Company and ENDRA Life Sciences Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
STAAR Surgical Company 3.17% 5.6% 3.8%
ENDRA Life Sciences Inc. 0.00% -405.7% -274.9%

Liquidity

STAAR Surgical Company has a Current Ratio of 5.3 and a Quick Ratio of 4.8. Competitively, ENDRA Life Sciences Inc.’s Current Ratio is 0.6 and has 0.6 Quick Ratio. STAAR Surgical Company’s better ability to pay short and long-term obligations than ENDRA Life Sciences Inc.

Institutional & Insider Ownership

Roughly 86.5% of STAAR Surgical Company shares are owned by institutional investors while 13.5% of ENDRA Life Sciences Inc. are owned by institutional investors. STAAR Surgical Company’s share owned by insiders are 0.1%. Insiders Competitively, owned 4.4% of ENDRA Life Sciences Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
STAAR Surgical Company -9.79% -31.42% -31.01% 17.84% 103.5% 121.23%
ENDRA Life Sciences Inc. -35.05% -51.69% -20.37% 26.47% -45.87% -55.76%

For the past year STAAR Surgical Company has 121.23% stronger performance while ENDRA Life Sciences Inc. has -55.76% weaker performance.

Summary

STAAR Surgical Company beats ENDRA Life Sciences Inc. on 9 of the 10 factors.

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers minimally invasive intraocular lenses (IOLs), including foldable IOLs for use in minimally invasive cataract surgical procedures; aspheric IOLs that produce a clearer image than traditional spherical lenses; and nanoFLEX IOL, a single piece collamer aspheric optic, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices; and manufactures AquaFlow devices for the treatment of glaucoma. It markets its products to health care providers, including ophthalmic surgeons, vision centers, surgical centers, hospitals, government facilities, and distributors primarily under the STAAR, EVO Visian ICL, Evolution in Visual Freedom, Visian, Collamer, CentraFLOW, AquaPORT, nanoFLEX, nanoPOINT, Afinity, and AquaFLOW trademarks. The company sells products directly through its sales representatives in the United States, Japan, Spain, Germany, Canada, and the United Kingdom, as well as through independent distributors in approximately 60 countries. STAAR Surgical Company was founded in 1982 and is headquartered in Monrovia, California.

ENDRA Life Sciences Inc. develops photo- and thermo-acoustic medical technologies that bring new capabilities to existing ultrasound systems. Its photo-acoustic solutions help global medical researchers to screen and modify disease models with high image quality and volume scanning speed. The company offers the Nexus-128 system, a fully 3D imaging solution for imaging anatomy, physiology, and labeled molecular targets for institutions. Its thermo-acoustic technology is being developed to enable clinicians to use their existing ultrasound equipment to visualize tissue function, composition, and monitor various therapeutic interventions at the point of care. The company was incorporated in 2007 and is headquartered in Ann Arbor, Michigan.